Habibi Mohammad Amin, Naseri Alavi Seyed Ahmad, Mirjnani Mohammad Sina, Aliasgary Aliakbar, Delbari Pouria, Ahmadvand Muhammad Hussain, Hatami Sina, Hasan Zuha, Dmytriw Adam A, Kobets Andrew J
Department of Neurosurgery, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Department of Neurosurgery, School of Medicine, Emory University, Atlanta, Georgia, USA.
World Neurosurg. 2025 Feb;194:123497. doi: 10.1016/j.wneu.2024.11.080. Epub 2024 Dec 11.
The impact of statin pretreatment on outcomes for patients undergoing endovascular treatment of intracranial aneurysms remains uncertain. We aimed to conduct a systematic review and meta-analysis evaluating the efficacy and safety of statins in this population.
We searched the PubMed/MEDLINE, Embase, Scopus, and Web of Science databases from inception to August 1, 2024. This study compares the outcomes between statin users and nonusers undergoing endovascular aneurysm treatment.
Eight studies with 5862 patients were included. Complete occlusion rates after endovascular aneurysm treatment were similar between statin users and nonusers (pooled odds ratio [OR], 0.93; 95% confidence interval [CI], 0.70-1.23). Statin use was associated with a significantly increased risk of ischemic stroke (pooled OR, 1.51; 95% CI, 1.03-2.19, P = 0.03). No differences were seen in neurologic mortality (pooled OR, 0.74; 95% CI, 0.21-2.57; P = 0.63), all-cause mortality (pooled OR, 0.68; 95% CI, 0.16-2.90, P = 0.61), or retreatment rates (pooled OR, 0.76; 95% CI, 0.35-1.66; P = 0.49). Statin therapy was associated with decreased hemorrhagic complication (pooled OR, 0.45; 95% CI, 0.24-0.85; P = 0.01) but did not affect thrombosis risk (pooled OR, 1.28; 95% CI, 0.68-2.40; P = 0.45) and statin use decreased in-stent stenosis (OR, 2.31, 95% CI, 1.51-3.52; P = 0.001).
Statin pretreatment may decrease the risk of hemorrhagic complications and in-stent stenosis after endovascular aneurysm therapy but does not improve angiographic occlusion. An increased hazard of ischemic events was found. Further data are needed to validate these findings and clarify the role of statins in patients with aneurysms undergoing endovascular procedures.
他汀类药物预处理对接受颅内动脉瘤血管内治疗患者预后的影响仍不确定。我们旨在进行一项系统评价和荟萃分析,评估他汀类药物在该人群中的疗效和安全性。
我们检索了从数据库建立至2024年8月1日的PubMed/MEDLINE、Embase、Scopus和Web of Science数据库。本研究比较了接受动脉瘤血管内治疗的他汀类药物使用者和非使用者的预后。
纳入了8项研究,共5862例患者。他汀类药物使用者和非使用者在血管内动脉瘤治疗后的完全闭塞率相似(合并比值比[OR],0.93;95%置信区间[CI],0.70 - 1.23)。使用他汀类药物与缺血性卒中风险显著增加相关(合并OR,1.51;95%CI,1.03 - 2.19,P = 0.03)。在神经源性死亡率(合并OR,0.74;95%CI,0.21 - 2.57;P = 0.63)、全因死亡率(合并OR,0.68;95%CI,0.16 - 2.90,P = 0.61)或再次治疗率(合并OR,0.76;95%CI,0.35 - 1.66;P = 0.49)方面未发现差异。他汀类药物治疗与出血性并发症减少相关(合并OR,0.45;95%CI,0.24 - 0.85;P = 0.01),但不影响血栓形成风险(合并OR,1.28;95%CI,0.68 - 2.40;P = 0.45),且使用他汀类药物可降低支架内狭窄(OR,2.31,95%CI,1.51 - 3.52;P = 0.001)。
他汀类药物预处理可能会降低血管内动脉瘤治疗后出血性并发症和支架内狭窄的风险,但不会改善血管造影闭塞情况。发现缺血性事件的风险增加。需要更多数据来验证这些发现,并阐明他汀类药物在接受血管内手术的动脉瘤患者中的作用。